Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene
Dineke Westra1, Katherine A Vernon, Elena B Volokhina
1Department of Pediatric Nephrology, Radboud University Medical Centre, Nijmegen, The Netherlands. d.westra@cukz.umcn.nl
Abstract:
Atypical hemolytic uremic syndrome (aHUS) is a severe renal disorder that is associated with mutations in genes encoding proteins of the alternative complement pathway. Previously, we identified pathogenic variations in genes encoding complement regulators (CFH, CFI and MCP) in our aHUS cohort. In this study, we screened for mutations in the alternative pathway regulator CFHR5 in 65 aHUS patients by means of PCR on genomic DNA and sequence analysis. Potential pathogenicity of genetic alterations was determined by published data on CFHR5 variants, evolutionary conservation and in silico mutation prediction programs. Detection of serum CFHR5 was performed by western blot analysis and enzyme-linked immunosorbent assay. A potentially pathogenic sequence variation was found in CFHR5 in three patients (4.6%). All variations were located in short consensus repeats that might be involved in binding to C3b, heparin or C-reactive protein. The identified CFHR5 mutations require functional studies to determine their relevance to aHUS, but they might be candidates for an altered genetic profile predisposing to the disease.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Complement System
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Humoral Immune Responses
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...


